Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00832208
Show Display Options
Rank Status Study
1 Terminated Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis
Condition: Visceral Leishmaniasis
Intervention: Drug: Liposomal amphotericin B (Ambisome)

Indicates status has not been verified in more than two years